OPCH revenue growth slows to low-single-digits as CID headwinds persist; buyback doubled to $1B

Filed July 29, 2026 · Period ending June 30, 2026 · Compared to 10-Q Jul 30, 2025 · ~2 min read

Key Changes

• high

  Revenue growth decelerated sharply to 1.9% Q2 YoY (vs 15.4% prior year), driven by flat chronic revenue and high-single-digit acute growth. Management quantifies chronic inflammatory disease (CID) headwinds at ~$55M gross profit impact for full-year 2026 due to patient attrition and unfavorable therapy mix.

  MD&A: Revenue Growth & CID Headwinds verify on EDGAR →
• high

  Board doubled share repurchase authorization from $500M to $1B in January 2026. Company repurchased $167.5M in H1 2026 (vs $150M prior year) at lower average price of $21.26/share (vs $32.61), leaving $525M remaining under the program.

  Controls & Notes: Share Repurchase Program verify on EDGAR →
• high

  Refinanced First Lien Term Loan, extending maturity from October 2028 to September 2032 and reducing SOFR margin from 2.25% to 1.75% (50 bps). Revolver capacity more than doubled from $400M to $850M, with maturity extended to September 2030. Weighted average interest rate fell 115 bps to 5.40%.

  MD&A & Notes: Credit Facility Refinancing view on EDGAR →